3LE cheraliecl,^RRI gnda R. QUOLX E, et al. Redio empyalone verus combined chemotherapy and mdiot lerdpy in noneseetable non - small cel cancer [J]. LUNG CANCER,1999,suppl. ( 1 ) :10.
5Chan AM, Mac A J, Wu T et al. Meta - analysis comparing carboplatin and cisplatin - based chemotherapy in advanced non. Small cell lung cancer [J]. Proc Am Soc Clin Oncol,2005,23:674 ( Abstr72181 ).
1Douillard. JY, Rosell R, Delena M, et al. ANITA: Phase Ⅲ adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage Ⅰ-Ⅲ) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Proc Am Soc Clin Oncol,2005,23:624(Abstr7013).
2Pisters K, Vallieres E, Bunn P et al. S9900: A phase Ⅲ trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. Proc Am Soc Clin Oncol,2005,23:624(Abstr LBA7012).
3Chan AM, Mao AJ, Wu T et al. Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol,2005,23:674(Abstr 7218).
4Kosmidis PA, Kalofonos C, Syrigos K, et al. Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase Ⅲ randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol,2005,23:621(Abstr 7000).
5Gandara DR, Chansky K, Gaspar LE, et al. Long term survival in stage Ⅲb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). Proc Am Soc Clin Oncol,2005,23:635(Abstr 7059).
6Sekine I, Nokihara H, Sumi M, et al. Docetaxel (D) consolidation therapy following cisplatin (P), vinorelbine (V) and concurrent thoracic radiotherapy (TRT) in patients with unresectable stage Ⅲ non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol,2005,23:651(Abstr 7125).
7Rosell R, Cobo M, Isla D, et al. ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage Ⅳ non-small-cell lung cancer (NSCLC) patients (p). Proc Am Soc Clin Oncol,2005,23:621(Abstr 7002).
8Albain KS, Swarm RS, Rusch VR, et al. Phase Ⅲ study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage ⅢA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). Proc Am Soc Clin Oncol,2005,23:624(Abstr 7014).
9van Meerbeeck JP, Kramer G, van Schil PE, et al. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage ⅢA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). Proc Am Soc Clin Oncol,2005,23 :624(Abstr LBA7015).
10Lynch TJ, Bell D, Haber D, et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. Proc Am Soc Clin Oncol,2005,23:622(Abstr 7006).
